How Structural Forces Are Reshaping the Global Medtech Industry in 2026

Executive Summary

The medical technology sector is entering a period of accelerated change. Driven by pricing policy shifts in China, the migration of procedures to outpatient settings, supply chain realignments, the behavioral impact of GLP-1 therapies, and the rise of platform-based competition, medtech companies must rethink their strategies. This article examines the five key trends identified in Clarivate's Medtech Trends to Watch 2026 and analyzes their implications for corporate strategy, investment, and long-term competitiveness.

Introduction

The global medical technology industry stands at a crossroads. As we approach 2026, forces that once seemed peripheral are now central to how companies compete: innovative pricing mechanisms, changing sites of care, geopolitical supply chain pressures, pharmacological innovations that alter patient pathways, and the deepening integration of digital technologies. These are not isolated phenomena but interconnected structural shifts that demand a comprehensive strategic response.

Market Context

The medtech landscape is being shaped by five major trends. First, mainland China’s volume-based procurement (VBP) program has evolved from a simple cost-containment measure into a powerful instrument that influences global pricing expectations. Second, the shift of procedures to outpatient and ambulatory surgical centers (ASCs) is accelerating, driven by regulatory changes in the United States. Third, global trade tensions and supply chain vulnerabilities are prompting manufacturers to diversify production footprints. Fourth, the rapid adoption of GLP-1 receptor agonists is transforming the management of metabolic disease, with ripple effects across multiple device markets. Fifth, enabling technologies such as robotics and digital workflows are redefining competitive advantage, moving from procedure support to platform ecosystems.

Main Analysis

China’s VBP Expansion: A New Global Pricing Paradigm

China’s volume-based procurement program, originally designed to expand patient access and reduce costs, is now a major structuring force in global medtech markets. The latest national VBP round incorporates more sophisticated anchor-price logic, deeper price compression, and allocation systems that favor domestic manufacturers. For multinational companies, the implications extend far beyond China: VBP is setting a benchmark for price and volume expectations in other emerging markets and in global procurement negotiations. Companies must increasingly treat VBP as a strategic factor when designing their global portfolio, pricing strategies, and market access approaches.

Outpatient and ASC Migration: Redefining Procedure Economics

The migration of procedures from hospitals to outpatient settings is a long-term trend that is now being reinforced by policy. The U.S. Centers for Medicare & Medicaid Services' 2026 OPPS/ASC Final Rule expands the list of ASC-covered procedures and phase-out of the inpatient-only list. This enables higher-acuity procedures such as cardiac ablation to be performed in lower-cost settings. For medtech companies, this is not merely a distribution shift; it changes the economic value proposition of devices, the commercial model, and product design. Manufacturers must address the needs of ASCs: ease of use, reliability, smaller footprints, and cost-effectiveness. This trend also creates opportunities for growth in orthopedics, cardiology, and other specialties.

Supply Chain Pressures and Manufacturing Strategy

Global trade disputes, tariffs, and geopolitical instability have exposed the vulnerabilities of concentrated manufacturing footprints. Medtech companies are responding by diversifying sourcing, rebalancing portfolios, and investing in multi-region production. The ability to manage supply chain risk is becoming a competitive differentiator. Larger players are leveraging scale and technology to increase resilience, which may accelerate consolidation and leave smaller companies at a disadvantage. Tariff exposure and material costs are now central to manufacturing strategy, influencing decisions on where to produce and how to price products globally.

GLP-1 Therapies and the Remodeling of Care Pathways

The rise of GLP-1 receptor agonists for weight management and metabolic disease is having an uneven but profound impact on medical technology. While bariatric surgery remains the gold standard for substantial weight loss, the increasing use of these drugs is changing referral patterns and procedure volumes. Some bariatric procedures are experiencing sharper volume pressure than others, and downstream effects in areas like diabetes care, sleep apnea, and cardiovascular monitoring are beginning to emerge. Medtech companies must closely monitor patient flows and adapt their portfolios to align with new clinical pathways.

Enabling Technologies and Platform-Based Competition

Robotics, imaging, navigation, and digital workflow software are no longer optional enhancements; they are becoming the core of integrated ecosystems that span the entire patient journey. Companies are investing in platform architectures that anchor service lines, deepen customer relationships, and unlock data-driven insights. Emerging open-platform systems are introducing new flexibility and shifting competitive dynamics. Success in this environment requires not only technological excellence but also the ability to orchestrate partnerships, data interoperability, and clinical integration.

Business Impact

These trends carry substantial implications for corporate strategy, commercial operations, and investment decisions. Pricing pressure in China forces companies to reassess portfolio profitability and resource allocation. The shift to outpatient care changes the sales and marketing model, emphasizing health economics and demonstrating value to provider-administered settings. Supply chain realignment requires capital investment and operational flexibility. The GLP-1 effect requires proactive portfolio management and strategic forecasting. Platform-based competition demands significant R&D investment and strategic alliances. Each of these factors affects long-term competitiveness and market positioning.

Executive Insights

For medtech executives, the strategic priorities are clear: embed market access considerations into early-stage product development, adopt a modular approach to product design that serves multiple sites of care, and build supply chains that can withstand geopolitical shocks. Diversification will be key, both geographically and technologically. Companies must also invest in digital capabilities that generate real-world evidence and support value-based reimbursement. Leadership will be challenged to navigate the tension between short-term financial performance and the long-term investment required to compete in a platform-based ecosystem.

Future Outlook

Looking ahead to the next 3–10 years, these trends are likely to intensify. China’s VBP will continue to evolve, potentially expanding into new categories and becoming a model for other Asian and emerging markets. The outpatient shift will accelerate as technology enables more procedures to be safely performed outside hospitals. Supply chains will become more regionalized, with companies maintaining redundant manufacturing sites. GLP-1s may expand into new indications, further altering procedure volumes and creating new monitoring and delivery opportunities. Platform competition will define the industry landscape, with data and digital ecosystems becoming as important as hardware. Companies that anticipate these changes and adapt their strategies accordingly will be better positioned to thrive in a complex and dynamic global market.

Conclusion

The global medtech industry is being transformed by powerful structural forces. The trends highlighted by Clarivate for 2026 are not isolated; they are interconnected across markets, care settings, and technologies. Medtech companies must approach these challenges strategically, integrating market access, supply chain resilience, and digital innovation into their core business models. Those that do will not only survive but also gain a sustainable competitive advantage in the evolving global healthcare economy.